Quarterly report pursuant to Section 13 or 15(d)

Earnings (Loss) Per Common Share (Tables)

v3.19.3.a.u2
Earnings (Loss) Per Common Share (Tables)
 6 Months Ended
Dec. 31, 2019
Earnings (Loss) Per Common Share  
Schedule of Earnings (loss) Per Share, Basic and Diluted

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months ended

 

Six Months ended

 

 

December 31, 

 

December 31, 

 

    

2019

    

2018

    

2019

    

2018

Basic and diluted numerator:

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

  

 

 

  

 

 

  

 

 

  

Net loss attributable to iBio, Inc.

 

$

(3,762)

 

$

(4,469)

 

$

(8,225)

 

$

(8,867)

Deemed dividends – down round of Series A  Preferred and Series B Preferred

 

 

(21,560)

 

 

 —

 

 

(21,560)

 

 

 —

  Preferred stock dividends – iBio CMO   Preferred Tracking Stock

 

 

(65)

 

 

(65)

 

 

(131)

 

 

(131)

Net loss available to iBio, Inc. stockholders

 

$

(25,387)

 

$

(4,534)

 

$

(29,916)

 

$

(8,998)

 

 

 

  

 

 

  

 

 

  

 

 

  

Basic and diluted denominator:

 

 

  

 

 

  

 

 

  

 

 

  

 

 

 

  

 

 

  

 

 

  

 

 

 

Weighted-average common shares outstanding

 

 

36,917

 

 

18,688

 

 

29,420

 

 

18,291

 

 

 

  

 

 

  

 

 

  

 

 

  

Per share amount

 

$

(0.69)

 

$

(0.24)

 

$

(1.02)

 

$

(0.49)

 

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

 

 

 

 

 

 

 

December 31, 

 

    

2019

    

2018

 

 

(in thousands)

Stock options

 

1,259

 

1,311

Series A Warrants

 

21,930

 

 —

Series B Warrants

 

24,930

 

 —

Series A Preferred

 

60

 

5,603

Series B Preferred

 

28,925

 

6,428

Series C Preferred

 

100

 

 —

Shares excluded from the calculation of diluted loss per share

 

77,204

 

13,342